Impact of HPV vaccination: Achievements and future challenges

Brotherton, Julia

doi:10.1016/j.pvr.2019.04.004

Cited by 29 publications

(23 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Statistical data from the recent years show that utilization of HPV vaccines is very effective for preventing infection and disease related to the specific HPV genotypes [78]. Vaccination programs have been very successfully implemented in many countries all over the world [78, 79].…”

Section: Hpv Vaccinationmentioning

confidence: 99%

“…At the present time, we have an abundance of evidence from multiple countries, with a different level of HPV vaccination coverage and implementation strategies that show the vaccines are effective [78]. In developing countries with long-standing screening programs, catch-up vaccination cohorts and established registration have demonstrated reductions in the diagnosis of CIN in screening women due to vaccination [78]. For example, the researchers from Scotland show a reduction of low- and high-grade CIN associated with high uptake of the HPV bivalent vaccine at the population level [83].…”

Section: Hpv Vaccinationmentioning

confidence: 99%

“…There are also apparent limitations and the public health challenges in attempting to implement HPV vaccination programs. These limitations and challenges include the vaccine's type specificity, required to be given prior to exposure, the three-dose schedule, ethical issues in targeting age group of early adolescence, and potential communication challenges around HPV being a sexually transmitted infection [78]. Therefore, large groups of women in advanced age who have not received vaccination are still under the risk of cervical cancer development.…”

Section: Hpv Vaccinationmentioning

confidence: 99%

See 2 more Smart Citations

Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination—Review of Current Perspectives

Chan

Aimagambetova

Ukybassova

et al. 2019

Journal of Oncology

309

235

View full text Add to dashboard Cite

Viral infections contribute as a cause of 15–20% of all human cancers. Infection by oncogenic viruses can promote different stages of carcinogenesis. Among many types of HPV, around 15 are linked to cancer. In spite of effective screening methods, cervical cancer continues to be a major public health problem. There are wide differences in cervical cancer incidence and mortality by geographic region. In addition, the age-specific HPV prevalence varies widely across different populations and showed two peaks of HPV positivity in younger and older women. There have been many studies worldwide on the epidemiology of HPV infection and oncogenic properties due to different HPV genotypes. However, there are still many countries where the population-based prevalence has not yet been identified. Moreover, cervical cancer screening strategies are different between countries. Organized cervical screening programs are potentially more effective than opportunistic screening programs. Nevertheless, screening programs have consistently been associated with a reduction in cervical cancer incidence and mortality. Developed countries have achieved such reduced incidence and mortality from cervical cancer over the past 40 years. This is largely due to the implementation of organized cytological screening and vaccination programs. HPV vaccines are very effective at preventing infection and diseases related to the vaccine-specific genotypes in women with no evidence of past or current HPV infection. In spite of the successful implementation of the HPV vaccination program in many countries all over the world, problems related to HPV prevention and treatment of the related diseases will continue to persist in developing and underdeveloped countries.

show abstract

Section: Hpv Vaccinationmentioning

confidence: 99%

Section: Hpv Vaccinationmentioning

confidence: 99%

Section: Hpv Vaccinationmentioning

confidence: 99%

See 1 more Smart Citation

Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination—Review of Current Perspectives

Chan

Aimagambetova

Ukybassova

et al. 2019

Journal of Oncology

309

235

View full text Add to dashboard Cite

show abstract

“…2 Data from recent years show that HPV vaccination is very effective in preventing infection and disease related to specific HPV genotypes. 3 Data from developed countries, including Australia, Canada, USA, and Sweden, demonstrate vaccine effectiveness and show a decrease in prevalence in targeted types following HPV vaccination. 1 In developing countries, however, there are many challenges in implementing vaccination, including financial limitations.…”

Section: Introductionmentioning

confidence: 99%

Cervical cancer screening and prevention in Kazakhstan and Central Asia

et al. 2020

View full text Add to dashboard Cite

Objective To examine the state of cervical screening and prevention in Central Asian states, specifically Kazakhstan. Results In the five Central Asian countries that were formerly part of the Soviet Union (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan), cervical cancer incidence and mortality rates are far higher than those in most Western and high-income nations, and are increasing. Cervical cancer screening is available in all five countries, but is mainly opportunistic. Only Kazakhstan has a structured cytological screening program, from which screening coverage analysis is possible. Conclusion Despite significant decreases in cervical cancer incidence and mortality in developed countries, the problem is still of great concern in these Central Asian countries and is attributed to poorly organized screening and the absence of vaccination programs.

show abstract

“…Most high-income countries have now implemented large-scale prophylactic vaccination initiatives. Brotherton [9] comprehensively summarises the extraordinary success experienced to date with HPV vaccination initiatives, across multiple countries, for health outcomes including HPV infection prevalence, anogenital warts and cervical precancerous lesions (cervical intraepithelial neoplasia, CIN2/3). She also deals with current challenges of surveillance for cancer outcomes – there are some complexities in detecting changes in rates of HPV-related cancer in the post-vaccination era, and these include the requirement to have a large enough base population to detect differences in cancer rates in younger people (where vaccination effects will be initially seen), and the complexities in surveillance of vaccination impact introduced by the effects of earlier detection of invasive cervical cancer in countries who have transitioned to HPV-based screening.…”

Section: Introductionmentioning

confidence: 99%